The COVID19 pandemic, designated as a public health crisis by the World Health Organization (WHO), is rapidly spreading around the world impacting the health and economy of almost all the countries. The data of hospitalized COVID19 patients, especially those with serious illness, indicate the involvement of immunopathological complications. As no effective treatment is currently available, we propose ‘Primed’ Mesenchymal Stem Cells (MSCs) as a therapeutic alternative to tackle devastating epidemic. The individual response to MSCs treatment is heterogeneous. During the treatment of infectious pathology, the effectiveness of the treatment may vary based on the disease scenario. Interestingly, when transplanted in vivo, MSCs are governed by the locally regulated microenvironment, suggesting that the restorative variability could be tailored by choosing a priming regimen to specifically correct a given pathology. Therefore, in our opinion, the priming of MSCs could be a novel approach to improve the responses of COVID19 patients.

被世界卫生组织 (WHO) 指定为公共卫生危机的 COVID19 大流行正在世界范围内迅速蔓延，影响了几乎所有国家的健康和经济。住院 COVID19 患者的数据，尤其是重症患者的数据表明存在免疫病理并发症。由于目前没有有效的治疗方法，我们建议使用“Primed”间充质干细胞 (MSCs) 作为治疗毁灭性流行病的替代疗法。对 MSCs 治疗的个体反应是异质的。在感染病理学的治疗过程中，治疗的有效性可能会因疾病情况而异。有趣的是，当体内移植时，MSCs 受局部调节的微环境控制，表明可以通过选择引发方案来专门纠正给定的病理学来调整恢复性变异性。因此，我们认为，MSCs 的启动可能是一种改善 COVID19 患者反应的新方法。